ClinicalTrials.gg
CompletedNCT03216278Updated May 30, 2018

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

A Phase 1 interventional study of Dapagliflozin/metformin XR 5/500mg and Dapagliflozin/metformin XR 5/500 mg in Healthy Subjects in Fasted and Fed State, sponsored by AstraZeneca. Completed at 1 site in Brazil. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a bioequivalence study of two doses of the dapagliflozin/metformin XR tablet manufactured at two different plants.

Read the detailed description

This is a two part, open-label, randomized, 4-period, 4-treatment (per study part) crossover study in healthy subjects (males and females of non-childbearing potential), performed at a single study center, conducted to establish the bioequivalence of 2 strengths of dapagliflozin/metformin XR tablets manufactured at two different plants.

02

Conditions studied

  • Healthy Subjects in Fasted and Fed State

Keywords

  • healthy,
  • fasted,
  • fed
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study-specific procedures
  2. Healthy male and female subjects aged 18 - 50 years with suitable veins for cannulation or repeated venipuncture
  3. Females must have a negative serum pregnancy test at screening and negative urine pregnancy test on admission to the unit, must not be lactating and must be of non-, confirmed at screening by fulfilling 1 of the following criteria:

    • defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the post menopausal range
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation
  4. Have a (BMI) between 18.50 and 24.90 kg/m2 inclusive [15% variance on the upper limit is permitted (i.e., up to 28.63 kg/m2)] and weigh between 50 and 100 kg inclusive at screening

Exclusion criteria

Exclusion Criteria

  1. History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP
  4. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the investigator
  5. Any clinically significant abnormal findings in vital signs, as judged by the investigator
  6. Any clinically significant abnormalities on 12-lead (ECG) as judged by the investigator
  7. Any positive result on screening for serum surface antigen (HBsAg), antibody and (HIV) antibody
  8. Severe hepatic insufficiency and/or significant abnormal liver function defined as (AST) >3x (ULN) and/or alanine aminotransferase (ALT) >3x ULN
  9. Total >2.0 mg/dL (34.2 µmol/L)
  10. Known or suspected history of drug abuse, as judged by the investigator
  11. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose.

    Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

  12. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  13. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to dapagliflozin/metformin XR.
  14. Current smokers or those who have smoked or used nicotine products within the 3 months prior to screening.
  15. Positive screen for drugs of abuse or alcohol at screening or on each admission to the study center
  16. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP
  17. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, vitamins and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life Note: Hormonal replacement therapy is allowed for females.
  18. Known or suspected history of alcohol abuse or excessive intake of alcohol, as judged by the investigator
  19. Inclusion of any AstraZeneca or study site employee or their close relatives
  20. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements
  21. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Treatment A

    Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed

    Drug: Dapagliflozin/metformin XR 5/500mg

  • Active comparator
    Treatment B

    Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed

    Drug: Dapagliflozin/metformin XR 5/500 mg

  • Experimental
    Treatment C

    Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted

    Drug: Dapagliflozin/metformin XR 5/500mg

  • Active comparator
    Treatment D

    Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted

    Drug: Dapagliflozin/metformin XR 5/500mg

  • Experimental
    Treatment E

    Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed

    Drug: Dapagliflozin/metformin XR 10/1000mg

  • Active comparator
    Treatment F

    Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed

    Drug: Dapagliflozin/metformin XR 10/1000mg

  • Experimental
    Treatment G

    Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted

    Drug: Dapagliflozin/metformin XR 10/1000mg

  • Active comparator
    Treatment H

    Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted

    Drug: Dapagliflozin/metformin XR 10/1000mg

Interventions

  • DrugDapagliflozin/metformin XR 5/500mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Mt Vernon plant

  • DrugDapagliflozin/metformin XR 5/500 mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Humacao plant

  • DrugDapagliflozin/metformin XR 5/500mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Dapagliflozin/metformin XR 5/500mg Mount Vernon plant

  • DrugDapagliflozin/metformin XR 5/500mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Humacao plant

  • DrugDapagliflozin/metformin XR 10/1000mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Mount Vernon plant

  • DrugDapagliflozin/metformin XR 10/1000mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Humacao plant

  • DrugDapagliflozin/metformin XR 10/1000mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Dapagliflozin/metformin XR 10/1000mg Mount Vernon plant

  • DrugDapagliflozin/metformin XR 10/1000mg

    Tablets for oral administration, once daily, once per treatment period

    Also known as: Dapagliflozin/metformin XR 10/1000mg Humacao plant

06

What researchers measure

Primary outcomes

  1. Part 1 - Area under the plasma concentration versus time curve (AUC) for each analyte and each state

    To demonstrate the bioequivalence of dapagliflozin/metformin XR 5/500 mg manufactured at Mount Vernon plant and dapagliflozin/metformin XR 5/500 mg manufactured at Humacao plant in metformin and in dapagliflozin plasma concentrations for the fed state and, separately, the fasted state.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  2. Part 2 - Area under the plasma concentration versus time curve (AUC) for each analyte and each state

    To demonstrate the bioequivalence of dapagliflozin/metformin XR 10/1000 mg manufactured at Mount Vernon plant and dapagliflozin/metformin XR 10/1000 mg manufactured at Humacao plant in metformin and dapagliflozin plasma concentrations for the fed state and, separately, the fasted state.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  3. Part 1 - Peak Plasma Concentration (Cmax) for each analyte and each state

    To demonstrate the bioequivalence of dapagliflozin/metformin XR 5/500 mg manufactured at Mount Vernon plant and dapagliflozin/metformin XR 5/500 mg manufactured at Humacao plant in metformin and in dapagliflozin plasma concentrations for the fed state and, separately, the fasted state.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  4. Part 2 - Peak Plasma Concentration (Cmax) for each analyte and each state

    To demonstrate the bioequivalence of dapagliflozin/metformin XR 10/1000 mg manufactured at Mount Vernon plant and dapagliflozin/metformin XR 10/1000 mg manufactured at Humacao plant in metformin and in dapagliflozin plasma concentrations for the fed state and, separately, the fasted state.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

Secondary outcomes

  1. Area under plasma concentration - time curve from time zero to infinity (AUC)

    Measurements of AUC from time zero to infinity for dapagliflozin and metformin when administered as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  2. Adverse events

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing the number of subjects with adverse events.

    Time frame: 10,5 weeks

  3. Blood pressure

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in mmHg of systolic and diastolic blood pressure.

    Time frame: 10,5 weeks

  4. Electrocardiogram (ECG)

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in overall ECG evaluation.

    Time frame: 10,5 weeks

  5. Time to reach maximum plasma concentration (tmax)

    Measurements of tmax for dapagliflozin and metformin when administered in both fed and fasted states as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  6. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

    Measurements of half-life associated with terminal slope (t½λz) for dapagliflozin and metformin when administered in both fed and fasted states as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  7. Terminal elimination rate constant (λz)

    Measurements of terminal elimination rate constant (λz) for dapagliflozin and metformin when administered in both fed and fasted states as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  8. Apparent total body clearance after extravascular administration (CL/F)

    Measurements of apparent total body clearance after extravascular administration (CL/F) for dapagliflozin and metformin when administered in both fed and fasted states as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  9. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    Measurements of apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) for dapagliflozin and metformin when administered in both fed and fasted states as single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants.

    Time frame: Based on pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose sampling times

  10. Laboratory assessments - hematology

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in hematology.

    Time frame: 10,5 weeks

  11. Heart rate

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in heart rate measured as beats per minute.

    Time frame: 10,5 weeks

  12. Laboratory assessments - clinical chemistry

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in clinical chemistry.

    Time frame: 10,5 weeks

  13. Laboratory assessments - urinalysis

    To evaluate the safety of single doses of dapagliflozin/metformin 5/500 mg or 10/1000 mg formulation from both the Mount Vernon and Humacao plants both fed and fasted states by assessing changes from baseline in urinalysis.

    Time frame: 10,5 weeks

07

Study locations

1 site
  • Research Site
    Aparecida de Goiania, 74935-530, Brazil
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in May 2018, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2017
First posted
Jul 13, 2017
StartActual
Sep 26, 2017
Primary completionActual
May 22, 2018
CompletionActual
May 22, 2018
Last update
May 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03216278
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 13, 2017
Start date
Sep 26, 2017
Primary completion
May 22, 2018
Completion
May 22, 2018
Last update
May 30, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion